Beam Therapeutics Inc. Common Stock
BEAM
BEAM: Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing.
moreShow BEAM Financials
Recent trades of BEAM by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by BEAM's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Compositions and methods for treating hemoglobinopathies May. 31, 2022
-
Patent Title: Adenosine deaminase base editors and methods of using same to modify a nucleobase in a target sequence Oct. 26, 2021
-
Patent Title: Compositions and methods for treating hemoglobinopathies Oct. 12, 2021
Federal grants, loans, and purchases
Followers on BEAM's company Twitter account
Number of mentions of BEAM in WallStreetBets Daily Discussion
Recent insights relating to BEAM
Recent picks made for BEAM stock on CNBC
ETFs with the largest estimated holdings in BEAM
Flights by private jets registered to BEAM